EP2621932A4 - TETRACYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION - Google Patents
TETRACYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONInfo
- Publication number
- EP2621932A4 EP2621932A4 EP11828123.7A EP11828123A EP2621932A4 EP 2621932 A4 EP2621932 A4 EP 2621932A4 EP 11828123 A EP11828123 A EP 11828123A EP 2621932 A4 EP2621932 A4 EP 2621932A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hepatitis
- treatment
- virus infection
- heterocyclic compounds
- tetracyclic heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2010/077498 WO2012040924A1 (en) | 2010-09-29 | 2010-09-29 | Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases |
| US201061426738P | 2010-12-23 | 2010-12-23 | |
| PCT/CN2011/080270 WO2012041227A1 (en) | 2010-09-29 | 2011-09-28 | Tetracyclic heterocycle compounds for treating hepatitis c viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2621932A1 EP2621932A1 (en) | 2013-08-07 |
| EP2621932A4 true EP2621932A4 (en) | 2014-03-26 |
Family
ID=45891961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP11828123.7A Withdrawn EP2621932A4 (en) | 2010-09-29 | 2011-09-28 | TETRACYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2621932A4 (en) |
| WO (1) | WO2012041227A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020031B1 (en) | 2009-06-11 | 2014-08-29 | Эббви Бахамаз Лтд. | Anti-viral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| CN102869657A (en) | 2010-03-24 | 2013-01-09 | 沃泰克斯药物股份有限公司 | Analogues for the treatment or prevention of flavivirus infections |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US8859595B2 (en) | 2010-08-26 | 2014-10-14 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis C virus |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CA2841095A1 (en) | 2011-07-09 | 2013-01-17 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| TWI610916B (en) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof |
| CN103848818B (en) | 2012-11-29 | 2017-03-15 | 广东东阳光药业有限公司 | Simultaneously cycle compound, pharmaceutical composition and their applications in medicine as hepatitis c inhibitor |
| CN103848821B (en) | 2012-11-29 | 2016-10-12 | 广东东阳光药业有限公司 | Spiro-compound, pharmaceutical composition and their purposes as hepatitis c inhibitor |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| WO2015089810A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2015110048A1 (en) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| KR102430183B1 (en) | 2014-09-26 | 2022-08-08 | 더 케무어스 컴퍼니 에프씨, 엘엘씨 | Isocyanate derived organosilanes |
| CN104478877B (en) * | 2014-10-31 | 2016-08-24 | 广东东阳光药业有限公司 | The method preparing Lei Dipawei intermediate |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CA3235146A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021928A2 (en) * | 2006-08-11 | 2008-02-21 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1719773E (en) * | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor |
| WO2006046039A2 (en) * | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| AU2008295483B2 (en) * | 2007-08-29 | 2013-11-21 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
-
2011
- 2011-09-28 WO PCT/CN2011/080270 patent/WO2012041227A1/en not_active Ceased
- 2011-09-28 EP EP11828123.7A patent/EP2621932A4/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008021928A2 (en) * | 2006-08-11 | 2008-02-21 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2012041227A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012041227A1 (en) | 2012-04-05 |
| EP2621932A1 (en) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2621932A4 (en) | TETRACYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | |
| EP2621931A4 (en) | TETRACYCLIC INDOLATE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | |
| EP2744332A4 (en) | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | |
| EP2658857A4 (en) | SUBSTITUTED PURIC NUCLEOSIDES, DERIVATIVES PHOSPHORAMIDATE AND PHOSPHORODIAMIDATE FOR THE TREATMENT OF VIRAL INFECTIONS | |
| EP2888240A4 (en) | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | |
| EP2552203A4 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| EP2633051A4 (en) | TREATMENT OF HBV INFECTION | |
| EP2385951A4 (en) | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| EP2558466A4 (en) | PHOSPHONATES HAVING REDUCED TOXICITY FOR THE TREATMENT OF VIRAL INFECTIONS | |
| MA37712B1 (en) | Macrocyclic inhibitors of flaviviridae virus | |
| EP2516430A4 (en) | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES | |
| EP2503881A4 (en) | FUSED TRICYCLIC COMPOUNDS AND THEIR DERIVATIVES USEFUL FOR THE TREATMENT OF VIRAL DISEASES | |
| EP2753618A4 (en) | HETEROCYCLE-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES | |
| EP2807252A4 (en) | METHODS FOR INCREASING INFECTION CAPACITY OF VIRUSES | |
| EP2816054A4 (en) | MACROCYCLIC COMPOUNDS FOR SUPPRESSING THE REPLICATION OF HEPATITIS C VIRUS | |
| EP2254582A4 (en) | METHODS OF TREATING VIRAL INFECTIONS | |
| EP2632452A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| EP2753611A4 (en) | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES | |
| EP2782578A4 (en) | METHOD FOR TREATING HEPATITIS C VIRUS INFECTION USING QUERCETIN-CONTAINING COMPOSITIONS | |
| EP2646043A4 (en) | NEW CICLOSPORINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION | |
| EP2953456A4 (en) | TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE FOR THE TREATMENT OF HEPATITIS C | |
| EP2534150A4 (en) | METHODS OF TREATING A VIRAL INFECTION | |
| EP2296654A4 (en) | 8-HYDROXYQUINOLINE DERIVATIVES FOR THE TREATMENT OF MALIGNANT HEMOPATHIES | |
| EP2341924A4 (en) | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | |
| EP2709619A4 (en) | COMPOUNDS FOR THE TREATMENT OF MUCOSITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20130429 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20140224 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/437 20060101ALI20140218BHEP Ipc: C07D 493/22 20060101ALI20140218BHEP Ipc: C07D 471/22 20060101ALI20140218BHEP Ipc: C07D 491/22 20060101ALI20140218BHEP Ipc: C07D 498/04 20060101AFI20140218BHEP Ipc: A61K 31/4985 20060101ALI20140218BHEP Ipc: C07D 471/04 20060101ALI20140218BHEP Ipc: A61K 31/5365 20060101ALI20140218BHEP Ipc: C07D 487/04 20060101ALI20140218BHEP Ipc: A61P 31/14 20060101ALI20140218BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20140924 |